← Leaderboards
Daniel Patrick Flaherty
Purdue University
$5,322,335
Attributed
$7,588,878
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,588,878 · 4
By mechanism
R01$7,151,000 · 3
R21$437,878 · 1
Top collaborators
- Val J Watts7 shared
- Paul M. Dunman5 shared
Most similar at Purdue University
Same institution · by research overlap
- Val J Watts$6,232,901
- Casey John Krusemark$3,050,197
Others in their field
Top investigators on “Scaffold”
- Vance G Fowler · Duke University$46,487,462
- Henry F Chambers · Duke University$46,487,462
- David Heimbrook · Leidos Biomedical Research, Inc.$38,175,159
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
- Steven Andrew McCarroll · Broad Institute, Inc.$27,107,011
- Erich J Stafford · Center For Construction Res And Training$25,637,539
Research focus
ScaffoldPharmaceutical ChemistryDesignIn VivoLead OptimizationAnalogMouse ModelPropertyReportingExhibitsInhibitorDrug KineticsEvaluationLiteratureResponseSeriesScreeningNew Therapeutic TargetStructureLeadValidationProtein IsoformsIn VitroGenetic
Grant awards (16)
Development of novel anti-Neisseria gonorrhoeae therapeutic agents$753,923
R01 · FY2025 · AI · contact PI
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$708,130
R01 · FY2025 · AI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$337,908
R01 · FY2025 · NS · contact PI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$69,619
R01 · FY2025 · NS · contact PI
Development of novel anti-Neisseria gonorrhoeae therapeutic agents$757,023
R01 · FY2024 · AI · contact PI
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$708,130
R01 · FY2024 · AI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$364,418
R01 · FY2024 · NS · contact PI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$63,436
R01 · FY2024 · NS · contact PI
Development of novel anti-Neisseria gonorrhoeae therapeutic agents$764,773
R01 · FY2023 · AI · contact PI
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$715,350
R01 · FY2023 · AI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$375,921
R01 · FY2023 · NS · contact PI
Development of novel anti-Neisseria gonorrhoeae therapeutic agents$780,073
R01 · FY2022 · AI · contact PI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$376,148
R01 · FY2022 · NS · contact PI
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic pain$376,148
R01 · FY2021 · NS · contact PI
Ribonuclease E a novel new Gram-negative antimicrobial target$231,630
R21 · FY2017 · AI
Ribonuclease E a novel new Gram-negative antimicrobial target$206,248
R21 · FY2016 · AI